Erlotinib and NSC23766 yield a synergistic antiproliferative effect in human glioblastoma cell lines by inhibiting cell cycle progression

Georg Karpel-Massler, Mike-Andrew Westhoff, Annika Dwucet, Christian Rainer Wirtz, Klaus-Michael Debatin & Marc-Eric Halatsch
Objective: We have previously reported that combined inhibition of the epidermal growth factor receptor by erlotinib and of RAC1 by NSC23766 yielded a synergistic antiproliferative effect on established and primary glioblastoma cells. The current study aimed at identifying the cellular and molecular[for full text, please go to the a.m. URL]